Spreading odontogenic infections with severe or systemic features (including Ludwig angina)

Severe features of a spreading odontogenic infection include significant facial swelling and pain, trismus, swelling of the neck, difficulty swallowing and difficulty breathing. Systemic features include pallor, sweating, tachycardia, and an axillary temperature above 38°C (oral temperatures are unreliable for infections originating in the mouth). The infection can rapidly become life threatening because of the risk of airway obstruction and sepsis. Ludwig angina is a severe spreading infection involving the bilateral submandibular, sublingual and submental spaces, with cellulitis.

Arrange urgent transfer of patients who have a spreading infection with severe or systemic features to a hospital that has an oral and maxillofacial surgeon or another appropriate expert.

Note: Arrange urgent transfer of patients with a spreading infection with severe or systemic features to a hospital that has an oral and maxillofacial surgeon or another appropriate expert.

Management of spreading infection with severe or systemic features involves:

  • maintaining a patent airway (do not lie the patient flat)
  • resuscitation
  • draining pus by incising affected spaces and placing drains
  • removing the tooth or otherwise addressing the source of infection
  • obtaining blood and other samples for culture and susceptibility testing
  • intravenous antibiotic therapy.

Spreading odontogenic infections can be associated with sepsis (for definitions, see here). For patients with sepsis, start antibiotic therapy within 1 hour of presentation to medical care; antibiotics should be given immediately after appropriate samples are taken for culture. Obtain blood samples and other relevant samples as soon as possible, but not if doing so will delay antibiotic administration. For nonantibiotic management of sepsis, see Early intervention for sepsis or septic shock.

For empirical antibiotic therapy of spreading odontogenic infection with severe or systemic features (including Ludwig angina), in conjunction with surgical intervention, use:

1 benzylpenicillin intravenously odontogenic infection benzylpenicillin    

patients requiring intensive care support: 2.4 g (child: 50 mg/kg up to 2.4 g) 4-hourly

patients not requiring intensive care support: 1.8 g (child: 50 mg/kg up to 1.8 g) 4-hourly

PLUS

metronidazole 500 mg (child: 12.5 mg/kg up to 500 mg) intravenously, 12-hourly odontogenic infection, spreading, with severe or systemic features metronidazole    

OR (as a single preparation)

2 amoxicillin+clavulanate intravenously odontogenic infection, spreading, with severe or systemic features amoxicillin + clavulanate    

2+0.2 g formulation

adult, or child 40 kg or more: 2+0.2 g 8-hourly

OR

1+0.2 g formulation

adult, or child 40 kg or more: 1+0.2 g 6-hourly

child 3 months or older and less than 40 kg: 25+5 mg/kg up to 1+0.2 g 6-hourly.

For patients who have had a nonsevere (immediate or delayed) hypersensitivity reaction to a penicillin, use:

cefazolin 2 g (child: 50 mg/kg up to 2 g) intravenously, 8-hourly; for patients requiring intensive care support, use 6-hourly dosing1 odontogenic infection cefazolin    

PLUS

metronidazole 500 mg (child: 12.5 mg/kg up to 500 mg) intravenously, 12-hourly. metronidazole    

For patients who have had a severe immediate2 hypersensitivity reaction to a penicillin, cefazolin plus metronidazole (at the dosages above) can be considered if a beta-lactam antibiotic is strongly preferred to clindamycin; for considerations, see Severe immediate hypersensitivity: Implications of cross-reactivity between penicillins and cephalosporins.

For patients who have had a severe immediate2 hypersensitivity reaction to a penicillin in whom cefazolin plus metronidazole is not used, or for patients who have had a severe delayed3 hypersensitivity reaction to a penicillin, use:

clindamycin 600 mg (child: 15 mg/kg up to 600 mg) intravenously, 8-hourly4. odontogenic infection, spreading, with severe or systemic features clindamycin    

Modify therapy based on the results of cultures and susceptibility testing. Switch to oral therapy once swelling and trismus subside (and the patient can swallow) and purulent discharge from the drains slows. If results of susceptibility testing are not available for oral continuation therapy, use the appropriate regimen here.

Stop oral antibiotic therapy once the drains are not producing any purulent discharge, signs and symptoms have resolved, the white cell count has returned to normal and the patient is afebrile.

1 Some patients with acute odontogenic infection will be critically ill. To ensure adequate drug exposure in these patients, modified dosages of cefazolin are recommended. This is because pharmacokinetics may be altered in critical illness (eg because of enhanced kidney clearance or changes in volume of distribution). Once the critical illness has resolved, consider switching to the standard dosage.Return
2 Severe immediate hypersensitivity reactions include anaphylaxis, compromised airway, airway angioedema, hypotension and collapse.Return
3 Severe delayed hypersensitivity reactions include cutaneous adverse drug reactions (eg drug rash with eosinophilia and systemic symptoms [DRESS], Stevens–Johnson syndrome/toxic epidermal necrolysis [SJS/TEN], severe blistering or desquamative rash), and significant internal organ involvement (eg acute interstitial nephritis).Return
4 There are more clinical and microbiological data to support the use of clindamycin than lincomycin. Intravenous lincomycin can be used at the same dosage if clindamycin is unavailable or if a local protocol recommends its use.Return